Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by VBI Vaccines

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VBI-1901

            Therapeutic Area: Oncology Product Name: VBI-1901

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            VBI-1901 continues to be well-tolerated with no vaccine-related safety signals observed at any dose.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VBI-1901

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            Presentation will highlight expanded immunologic and tumor response data as well as potentially-predictive biomarker data from the VBI-1901 + GM-CSF study arm in Part B of the ongoing Phase 1/2a study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VBI-2901

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            VBI completed the pivotal Phase 3 program for Sci-B-Vac® and is on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020. .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hepatitis B vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Raymond James & Associates

            Deal Size: $57.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 27, 2020

            Details:

            VBI intends to use the net proceeds to support the regulatory filings, pre-commercialization, and launch planning activities for Sci-B-Vac® and for other clinical and pipeline activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pan-coronavirus vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Recipient: National Research Council of Canada

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 31, 2020

            Details:

            The deal will combine VBI’s viral vaccine expertise, eVLP technology platform, and coronavirus antigens with NRC’s COVID-19 antigens and assay development capabilities to identify COVID-19 vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VBI-1901

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2020

            Details:

            The two-arm Phase 2a study is expected to enroll 20 first-recurrent GBM patients to receive VBI’s cancer vaccine candidate, VBI-1901, in combination with either GM-CSF or AS01B.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sci-B-Vac

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            The Phase 3 study, met both the primary and secondary endpoints. Sci-B-Vac achieved seroprotection rates of 99.3% and 90.4% after 3 and 2 doses, respectively, compared with 94.8% and 51.6% with Engerix.